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Abstract 
Oral vaccines offer significant benefits due to the ease of administration, better patient 
compliance and non-invasive, needle-free administration. However this route is marred by 
the harsh gastro intestinal environment which is detrimental to many vaccine formats.  To 
address this, a range of delivery systems have been considered including bilosomes; these are 
bilayer vesicles constructed from non-ionic surfactants combined with the inclusion of bile 
salts which can stabilise the vesicles in the gastro intestinal tract by preventing membrane 
destabilisation. The aim of this study was to investigate the effect of formulation parameters 
on bilosome carriers using Design of Experiments to select an appropriate formulation to 
assess in vivo. Bilosomes were constructed from monopalmitoyl glycerol, cholesterol, dicetyl 
phosphate and sodium deoxycholate at different blends ratios. The optimised bilosome 
formulation was identified and the potential of this formulation as an oral vaccine delivery 
system were assessed in biodistribution and vaccine efficacy studies. Results showed that the 
larger bilosomes vesicles (~6 µm versus 2 µm in diameter) increased uptake within the 
Peyer's patches and were able to reduce median temperature differential change and promote 
a reduction in viral cell load in an influenza challenge study.  
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Introduction 
An effective vaccine is one which prevents infection and disease through its capability to 
elicit specific immune responses and hence provide protective immunity (Bramwell and 
Perrie, 2005). However ease of use is also a key consideration for global vaccination 
campaigns. In this respect, oral vaccines offer significant benefits over traditional vaccines 
due to their ease of administration, improved patient compliance (due to their needle-free 
format), potentially enhanced mucosal immunity and strong resistance against many 
pathogens. Furthermore due to its non-invasive nature and ease of administration, the oral 
route can circumvent the need for trained personnel to administer the vaccine. However, the 
ability of many vaccines to withstand the harsh journey through the gastrointestinal tract, and 
to be effectively taken up in the appropriate target site is limited (Wilkhu et al, 2011). 
Therefore to circumvent this barrier, delivery systems can be employed. For example, lipid 
based vesicles such as liposomes or niosomes (non-ionic surfactant vesicles) can be used as 
effective carriers of macromolecules (Bramwell and Perrie, 2006). Yet, many of these 
constructs can be destabilised after exposure to intestinal bile salts, which have the potential 
to cause the membrane deformation and vesicle lysis, resulting in the release of 
macromolecules from the vesicle prior to reaching its intended site of action. In response to 
this, a range of modified lipid based vesicles, which have increased stability and increased 
absorption through the GIT, have been developed. Such vesicles include bilosomes, which 
have been shown to protect antigens from the enzymes present in the GIT and act as potent 
immunological adjuvants (Mann et al., 2009, Shukla et al., 2008, Mann et al., 2004). This has 
been attributed to the incorporation of bile salts into the vesicle bilayers, which increases 
resistance to degradation and disruption by digestive enzymes (Schubert et al., 1983).  
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For effective delivery of vaccines after oral administration, the target site for vaccines is the 
M cells located in the Peyer’s patches, which are responsible for secretory IgA and other 
mucosal responses  (Schmucker et al., 1996). As a result of bilosomes ability to protect and 
target antigens, smaller concentrations of the antigen can be used to provide an effective 
response relative to unformulated antigen given orally. This has been demonstrated by e.g. 
Conacher et al, 2001 who showed that including bile salts in the vesicle constructs had a 
stabilising role after oral administration by preventing degradation with highly acidic 
conditions and improving oral vaccine efficacy (Norris et al., 1998, Conacher et al., 2001).  
Similar studies have demonstrated this with a range of antigens e.g. tetanus toxoid (Mann et 
al., 2006), the A/panama (Mann et al., 2004), Diphtheria toxoid (Shukla et al., 2011) and 
hepatitis B (Shukla et al., 2010).  These studies all show that, by orally administering the 
bilosome vesicles with entrapped antigen, a mucosal immune response is elicited with 
specific IgA production increased. Therefore, bilosomes can aid vaccine technology by 
increasing the stability of the vaccine during transit through the GIT, preventing premature 
release and/or degradation of the antigen during oral transit (Wilkhu et al., 2011).  
 
From these studies several potential controlling parameters for the design of bilosome 
constructs become apparent: vesicle size is vital as this determines the end location of the 
vaccine when administered, the zeta potential and the vesicle pH is also important when 
determining the stability and absorption of the vaccine (Norris et al., 1998). Therefore within 
this study we have undertaken a systematic investigation into the effects of bilosome 
composition on their physico-chemical characteristics and the relationship between the 
factors influencing the bilosome composition and physiological and biological outcomes.  
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 Design of Experiments, using a d-optimal factorial design, was used to plan and conduct 
experiments in a random order and used to extract information on the relationship between 
formulation and function.  
 
Materials and methods 
Materials 
To form the vesicles the lipids monopalmitoyl glycerol (MPG; Larodan AG, Sweden), 
synthetic cholesterol (Chol), dicetyl phosphate (DCP) and sodium deoxycholate (bile salt) 
(Sigma-Aldrich, UK) were used. The buffers were made up of sodium bicarbonate (Sigma-
Aldrich, UK) at two specific pH, where hydrochloric acid and sodium hydroxide (NaOH) 
(Sigma-Aldrich, UK) was used for pH adjustments. For the antigen a recombinant HA or the 
H3N2 sub-unit protein (Immune Tech, USA) was used. 
 
Preparation of bilosomes.  
Bilosomes were prepared based on a modified method of Conacher et al, (Conacher et al., 
2001). Briefly, a hot paraffin oil bath was set up at 120 °C and alongside a water bath at 50 
°C. Two 25 mM sodium bicarbonate buffers were made up, one at a pH of 7.6 and the other 
with a pH of 9.7. The bile salt solution was prepared by making a 100 mM solution using the 
freshly made 25 mM sodium bicarbonate buffer of pH 9.7. Appropriate molar ratio of the 
lipids MPG, Chol and DCP were weighed and placed in a 25 mL flat bottom glass beaker 
ensuring no powder sticks to the sides of the glass beaker. The lipids were melted by heating 
at 120 °C for 10 minutes with occasional swirling.  
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While maintaining the molten lipid (308.5mg) at 120 °C, an emulsion was created by the 
addition of 5.2 mL of the 25 mM sodium bicarbonate pH 7.6 buffer (preheated to 50 °C) and 
immediately homogenised (using an emulsion head) for 2 minutes at 8000 rpm. While still 
homogenising 0.55 mL of 100 mM bile salt in 25 mM sodium bicarbonate buffer pH 9.7 was 
added and homogenised further for 3 minutes. After the 3 minutes homogenising, 0.25 mL 
(10 mg/mL) of the pre-heated (50 °C) antigen solution was added to the beaker containing the 
suspension, and homogenised for a further 5 minutes. The antigen was added at the final 
stage to minimise exposure of the antigen to homogenisation.  Once homogenisation had 
finished, the bilosome suspension was allowed to cool to 30 °C, and left for 2 hours in an 
incubator/shaker at 220 rpm.  
 
Characterization of vesicles. 
The size of the bilosomes was determined using laser diffraction on a sympatec 2005 
(Helos/BF) analyser. 20 µL of the bilosome suspension was diluted into the cuvette with 40 
mL double distilled water. The zeta potential, which is an indirect measurement of the vesicle 
surface charge, was measured in 1.5 mL double distilled water at 25 °C on a Zeta Plus 
Brookhaven Instrument. 20 µL of the bilosome suspension was mixed in 1.5 mL double 
distilled water and then analysed. The pH of the vesicle suspension was determined using a 
pH meter where the tip was placed into the bilosome suspension and left for a few minutes.  
Radiolabelling of H3N2 antigen 
To further quantify antigen incorporation, the antigen was radio-labelled using 125I. To 
achieve this antigen stock solutions were prepared as 100 µg (1mg/mL) in PBS stock and 40 
µL (40 µg) placed into an iodination tube (Pierce Biotechnology) with 2 Mbq for 1 hour and 
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subsequently separated from non-labelled antigen by column chromatography (Henriksen-
Lacey et al., 2010). 
Stability of the vesicles in simulated fasted gastric and intestinal medium 
Fasted state simulated gastric media (50 mL) was prepared using a 34.2 mM NaCl solution in 
50 mL HPLC water at pH 1.2 adjusted with 1 M HCl. Pepsin (40 mg) was then added, 
followed by sodium taurocholate (2.15 mg) and phosphatidylcholine (0.76 mg) in 50 mL at 
37 °C (Vertzoni et al., 2005).  
Fasted state simulated intestinal media (50 mL) was prepared by a 50 mM PBS solution in 50 
mL HPLC water at pH 8.5, adjusted with 1 M NaOH, and sodium glycodeoxycholate (180 
mg) and phosphatidylcholine (34 mg) dissolved in the solution at 37 °C. To establish the 
effect of these conditions on vesicle attributes, 400 µL of the vesicle formulations was added 
to 3.6 mL of Fasted gastric medium as a 1:10 dilution. The formulations were tested for 
vesicle size and zeta potential at specific time intervals. The gastric to intestinal phase was 
carried out by centrifuging 3.9 mL of the formulations from the gastric period and then 
resuspending the pellet in fasted intestinal fluid and was then tested at the stated time points. 
To measure antigen retention in these conditions, radio-labelled antigen was incorporated 
within the formulations and antigen retention tracked in the above conditions by 
ultracentrifugation (Beckaman, Ultima XP) at 100,000g. 
In vivo biodistribution protocol 
Inbred female Balb/c (6-10 weeks of age) mice were housed in cages within a laminar flow 
safety enclosure and provided with irradiated food and filtered drinking water. 
Experimentation adhered to the 1986 Scientific Procedures Act (UK). All protocols have 
been subject to ethical review and were carried out in a designated establishment. 200 µL 
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doses of the formulations, which were washed to remove unentrapped radiolabelled antigen, 
were given orally to Balb/c mice in groups of 4. Animals were terminated at various time 
points, organs collected and analysed for both 125I (to measure antigen) and 3H, which was 
used as a radio-active tracker for vesicles by incorporating 3H-cholesterol in the formulation.  
Gamma vials were pre-labelled and individual tissues/organs were weighed and individually 
placed into the gamma vials. To the gamma vials 1.5 mL of solvable was added to digest the 
tissues. Once the solvable was added to the vials they were then placed onto the gamma 
counter to record the 125I-antigen levels. The vials were then placed into an incubator at 50 °C 
overnight to dissolve the tissues. Once the tissues had dissolved the contents of the gamma 
vials were transferred to 20 mL scintillation vials where 200 µL hydrogen peroxide was 
added to each vial to bleach the samples. The vials were left overnight once again to wait for 
gas to disappear and 10 mL of scintillation fluid (Ultima Gold) was added to form an 
emulsion. The vials were then counted on the scintillation counter which will represent the 
counts for the vesicles at each site. 
Oral Vaccine study 
Bilosome vesicles were prepared with recombinant HA directed against influenza viruses as 
per protocol and were orally administered to ferrets on days 0, 3, 14, and 17, and 14 days 
later challenged with a clinical rHA isolate of influenza A.  As the key correlate of protection, 
median temperature differential was measured to follow protection against fever and 
inflammatory cell counts in nasal washes were measured.  
Statistical analysis 
The results within this study are given as the geometric mean ± S.D. unless stated otherwise. 
The DOE statistics were carried out using ANOVA based within the software MODDE 
(Umetrics). Differences between the biodistribution antigen levels were analysed by 
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ANOVA. A probability factor of less than 0.05 (P < 0.05) was considered to represent  
statistically significant difference. 
 
Results and Discussion 
Design of experiments response   
An experimental design consisting of MPG, Cholesterol, DCP and bile salt as the factors was 
generated with the responses tested being pH, vesicle size and zeta potential. MPG was 
always kept constant, at a molar ratio of 5, whereas the cholesterol, DCP and bile salt were 
varied. The experimental design consisted of three centre points to form the control, by 
appearing in a random order, with the same molar ratios for each of the factors. The centre 
points are calculated by taking the average of each factor for all the experimental runs and in 
turn will determine the accuracy and reproducibility of the experimental model that is 
calculated. 
The partial least squares (PLS) orthogonal coefficients of the bilosome composition on pH, 
zeta potential and vesicle size are shown in Fig 1A to C, respectively; these results show 
three significant variables which are highlighted from the results of the d-optimal factorial 
design that involve cholesterol, DCP and bile salt. In particular, the DCP and cholesterol 
content together are shown to have a significant impact on the pH and zeta potential (Fig 1A 
and B) with the P-value being less than 0.05 (Table 1). However, in terms of vesicle size, 
statistically the cholesterol and DCP ratio made no impact (Fig 1C; Table 1). Interestingly, 
only vesicle size was shown to be influenced by bile acid content; Figure 1C shows that bile 
salt has a negative impact, with an increase in bile salt content to the formulation reducing 
vesicle size.  
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In this study only DCP content was varied, the MPG and cholesterol ratios were kept constant 
at a ratio of 5:4 respectively and the bile salt content at 100 mM. Results in figure 3 show that 
DCP is the key factor controlling both the pH of the vesicle suspension and vesicle zeta 
potential, with increasing DCP content decreasing pH and reducing the negativity of 
bilosome zeta potential. This may be an outcome of the increasing DCP content, through its 
weakly acidic action, and dissociation of the +H ion reduces the pH of the suspension, thus as 
the DCP content increases, the pH drops, and this could, in turn, reduce the zeta potential. 
The impact of DCP on vesicle suspension pH has also been studied by (Kogure et al., 1997) 
and Manosroi et al, 2003. Manosroi et al, (2003) were developing a liposome formulation for 
tranexamic acid (TA) with various lipid compositions including negatively charged DCP 
lipid and a positively charged stearylamine (Manosroi et al., 2003).  One of the features of the 
study showed that negatively charged lipids (DCP) gave low pH values ranging from 3.4-7.1 
compared to the positively charged lipids (pH 7.6-7.9).   
To confirm this, the zeta potential of a fixed (5:4:1 MPG:Chol:DCP with 100 mM bile salt) 
bilosome formulation was investigated over a pH range from 1 to 10 and reversed again (Fig 
3B) and the results show that as we increase the pH from 1 to 10, the zeta potential of the 
vesicles changes from around   -15 mV to -120 mV confirming the controlling role of pH on 
the anionic nature of the bilosomes (Fig 3B). Therefore by varying the DCP content in the 
bilosome formulations, this modulates the pH of the suspension system which in turn impacts 
on the zeta potential of the bilosomes, thereby confirming that a continued increase in anionic 
surfactant content may not always promote increasing anionic zeta potential of vesicles. 
 
 
 
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 (a) Effect of changing DCP content on the pH and Zeta potential of the Bilosomes. 
(b) Effect of titrating acid on the pH and Zeta potential of the Bilosomes 
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In terms of how this impacts on biological responses, the zeta potential has been shown to 
influence the uptake of bilosomes in studies by Tomizawa et al. (1993) who have shown that 
negatively charged vesicles are preferably taken up by the Peyer's patches (Tomizawa et al., 
1993). Therefore, by incorporating appropriate levels of DCP into the formulation, it gives 
the bilosomes their negative charge, which can be retained throughout the various pH ranges 
of the GIT (Fig 3B) suggesting that this will aid in the uptake of the bilosomes by the Peyer's 
patches at the range of pH seen across the GIT. 
 
Effect of bile salt concentration on the vesicle size  
Given that figure 1C identified bile salt concentration as a key formulation parameter, this 
was further investigated in figure 4, particularly given that vesicle size range may be crucial 
in determining uptake of particles by Peyer’s patches; studies by Eldridge et al. (1990) on 
vesicle size uptake in the Peyer's patches show that uptake is dependent on the vesicle size 
and hydrophobicity (Eldridge et al., 1990). The results from their experiments indicate that a 
vesicle size of 10 µm or less are taken up by the Peyer’s patches, however particles with a 
size less than 4- 6 µm can traffic to other tissue cells by a process of lymphoid drainage. As a 
result, particles larger than 4-6 µm reside within the Peyer's patches, the vesicles formulated 
in this study fall within this size range. 
Figure 4 shows the volume mean distribution (VMD) of vesicles for each formulation, with 
all formulations in this study were made with a 5:4:1 ratio of lipids (MPG: Chol: DCP) with 
the bile salt concentration ranging from 0 to 800 mM. Results showing that as the bile salt 
concentration increases the vesicle size decreases, whist the size distribution was not 
significantly influenced. A previous study incorporating bile salt within lipid vesicles by 
Chen et al., (2009) has shown the same trend of decreasing vesicle size upon increased bile 
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salt concentration, with this being attributed to enhanced flexibility and a lowering of surface 
tension between the vesicles (Chen et al., 2009). However across the bile salt concentration 
range tested, the formulated bilosomes were generally in the 4-6 µm particle size range 
therefore should reside within the Peyer's patches as required for vaccine delivery (Fig 4C 
and D).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 (a) Effect of bile salt content on mean vesicle size distribution (VMD) with span, (b)  
Number frequency of the formulations with increasing bile salt content in relation to the 
VMD. (C and D) Freeze fracture and Confocal laser microscopy images showing population 
of vesicles within suspension. 
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Bilosome stability in simulated fasted gastric and intestinal conditions. 
In addition to the role of bile salt in controlling vesicle size, the primary reason for inclusion 
of bile salts was to investigate their potential to improve vesicle stability in the GI 
environment. Therefore, the characteristics of the bilosomes formulation (5:4:1 
MPG:Chol:DCP with 100 mM bile salt) were tracked in simulated gastric and intestinal 
conditions. Table 2 shows that the bilosome vesicle size increases from 6.44 ± 0.05 µm to 
11.9 ± 0.57 µm after exposure for 15 min in simulated gastric fluid but did not significantly 
increase in size thereafter (Table 2). The drop in pH in the simulated stomach conditions 
resulted in a reduction in zeta potential from -125 mV to -47 mV (Table 2). However when 
these bilosomes were transferred from the simulated gastric to the simulated intestinal 
environment, the bilosomes decreased back to their original size, and moved to a more 
negative, but not fully restored, zeta potential (Table 2). With regard to antigen incorporation, 
initial entrapment (based on initial amount added) shows that the bilosome formulation has 
an initial antigen loading of 32 %. When placed into the gastric media, no antigen was lost 
with the bilosomes maintain their antigen loading. However, when taken from gastric to 
intestinal medium, approximately 24 % of the antigen loading was lost, with antigen loading 
decreasing to 7.8-8.5 % (Table 2).  
The sharp decline in antigen loading with the bilosome formulation (Table 2) when taken 
from gastric to intestinal fluid at the same conditions could be an indication of the special 
location of antigen within the vesicles. In their manufacture, the antigen is incorporated via 
homogenisation of formed bilosomes, and therefore incorporation may be predominately 
associated with the outer regions of the vesicles or surface bound. Therefore, when the 
vesicles move from the gastric to intestinal conditions, degradation of antigen located on the 
surface may occur. 
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Table 2: In Vitro- Antigen retention studies accompanied by corresponding size and zeta 
potential at the specific time points for each media condition. 
Time 
(Min) 
  Vesicle Size  
(µm) 
Zeta Potential 
(mV) 
Antigen incorporation  
(% of initial antigen added) 
0 
Gastric 
m
edia 
6.44 ± 0.5  ‐125.0 ± 21  32.3 ± 1.2 
15  11.50 ± 0.5  ‐47.0 ± 6.7  36.0 ± 1.9 
30  11.31 ± 0.3  ‐45.4 ± 6.2  36.3 ± 0.9 
60  11.90 ± 0.6  ‐47.0 ± 8.6  36.2 ± 1.7 
75  Intestinal 
m
edia 
6.11 ± 0.6  ‐89.1 ± 21  8.7 ± 0.1 
90  5.36 ± 0.3  ‐89.4 ± 24  8.6 ± 0.1 
120  6.43 ± 0.5  ‐82.4 ± 10  9.2 ± 0.1 
300  5.14 ± 0.2  ‐85.1 ± 9.5  9.3 ± 0.1 
 
The delivery potential of bilosomes after oral administration. 
Using the optimised bilosome formulation, the ability of these vesicles to carry the antigen 
through the GIT and deliver it to the Peyer’s patch was investigated by tracking 125I-labelled 
antigen and 3H-labelled bilosomes. Mice were dosed with the various formulations via oral 
gavage and Fig 5 outlines the percentage of antigen with bilosomes, at time intervals of 30 
minutes, 1 hour and 4 hours in various regions of the GIT. In addition antigen, administered 
without vesicles, was measured at 1 hour to allow comparison (given its rapid clearance no 
other time points for antigen alone were considered).  
Figure 5A shows that after 30 min around 8 % of the vesicles can be found in the stomach 
and around 40 % found in the small intestine. With increasing time, the bilosomes can be 
seen to move from the small intestine into the cecum and colon (Fig 5A). With regard to the 
associated antigen, a similar trend is seen (Fig 5B), with the highest levels in the small 
intestine being measured after 30 min and 1 hour. However when antigen is delivered without 
a carrier, only low levels are measured across the GIT, with a total of 39 % being measured in 
the GIT compared to 55 % for antigen delivered with the bilosome carrier at the same time 
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point (Fig 5B), suggesting the free antigen is degraded and clearly quickly from the GIT. In 
particular, it is notable that higher levels of antigen were measured in the small intestine 
when incorporated into the bilosome carrier system.  
In terms of antigen targeting to the site of action, figure 5C shows antigen recovery at the 
Peyer's patches and mesenteric lymph tissue for the ‘free antigen’ compared to the antigen 
associated with bilosomes vesicles. Results show that by using the bilosome carrier, a 
significantly higher (p<0.05) level of antigen was measured within the mesenteric lymph 
tissue when delivered using the bilosome carrier compared to antigen given alone without a 
carrier system.  Interestingly whilst higher levels of bilosomes were measured in the Peyer’s 
patches compared to MSN, this did not translate to increased antigen levels, with comparable 
bilosome delivered antigen being measured in the Peyer’s patches and the MSN. This could 
be indicative of different trafficking of the antigen and bilosomes, potentially with the dose of 
surfactant having an impact on the amount of bilosomes moving to the MSN.  
The impact of vesicle size on oral distribution 
To investigate the impact of vesicle size, bilosomes were reduced in size via probe sonication 
to 1.88 µm and the distribution study repeated (Fig 6) using 30 min as the end point based on 
the results from figure 5. The antigen and vesicle recovery data suggests that the majority of 
the formulation after a 30 minute is present within the small intestine of mice, with 
approximately 10 % in the stomach (Fig 6). These results are in line with results for the larger 
(6.44 µm) vesicles (Fig 5A).  
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Figure 5. (A) vesicle recovery within organs after dosing regime including free antigen, (B) corresponding antigen recovery within the organs and (C) 
closer look at the Peyer’s patch uptake and Mesenteric lymph tissue recovery of antigen and vesicle after 1 h timepoint (*significant difference p < 
0.05). 
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Considering the target site uptake of antigen and carrier into the Peyer’s patch and mesenteric 
lymph tissue (Fig 6B), significantly higher (p<0.01) levels of the larger vesicles was found in 
the Peyer’s patches compared to the smaller vesicle size formulation (Fig 6B). However this 
did not translate into significantly increase the levels of bilosomes or antigen in the MSN. A 
similar trend has been observed by Ebel (1990) who compared the uptake of 9 µm and 2 µm 
polystyrene latex beads via the Peyer’s patches and Mesenteric lymph nodes. The results 
showed that the larger particles retained within the Peyer’s patches with no presence in the 
mesenteric lymph nodes, whereas the smaller particles were more noticeable in the 
mesenteric lymph nodes (Ebel, 1990). Further, in studies using PLA, Eldridge et al., (1990) 
demonstrated that Peyer’s patch uptake was restricted to particles less than 10 µm, however 
whilst particles between 5 and 10 µm remained within the Peyer’s patches, the majority of 
microspheres less than 5 µm were transported through the efferent lymphatics within 
macrophages, and suggest that this pattern of absorption and redistribution may determine the 
type of immune response elicited by the vaccines, with microspheres below 5 µm inducing a 
predominantly circulating antibody response, while those above this size would stimulate a 
mucosal (IgA) immune response (Eldridge et al., 1990). Therefore, the results in figures 5 
and 6 demonstrate that larger (~ 6 µm VMD) vesicles promote enhanced uptake and retention 
of both vesicles and antigen within the Peyer’s patch and mesentery lymph nodes potentially 
offering a greater chance to increase mucosal immunity.  
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Figure 6. (A) Antigen and vesicle recovery of a reduced bilosome vesicle formulation (1.88 μm) and (B) comparative data for large and small 
bilosome vesicles showing antigen and vesicle recovery after a 30 min timepoint (**highly significant difference p < 0.01). 
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Oral vaccination studies 
To investigate the efficacy of the optimized bilosome formulation, bilosomes containing the 
rHA directed against influenza viruses were administered to ferrets orally on days 0, 3, 14, 
and 17, and 14 days later challenged with a clinical rHA isolate of influenza.  To investigate 
the efficacy of the vaccine and comply with 3R protocols, the key correlate of protection, the 
Median temperature differential, was measured to follow protection against fever and 
inflammatory cell counts in nasal washes (Fig 7). The bilosome vaccine incorporating the 
rHA shows a reduced median temperature differential change compared to a dose of empty 
bilosomes suggesting that the antigen containing bilosomes via the oral route provided strong 
protection from fever. After analysing nasal washes for inflammatory cells, the bilosome plus 
rHA vaccine also promoted a reduction in viral cell load counts compared to bilosomes 
administered without antigen. Thus the bilosome formulation containing the influenza 
vaccine promoted protection against fever and suppressed lung inflammation to extents 
comparable to empty vesicles showing promising results for vaccine delivery via the oral 
route. 
Previous research has shown that delivering subunit antigens alone via the oral route does not 
sufficiently promote effective immune responses (Azizi et al., 2010). Indeed when 
considering recombinant influenza antigen, Amorij, et al (2007) have shown that the 
intragastric delivery of recombinant H3N2 antigen alone induced low HI titres, which were 
significantly lower than the antigen delivered IM (Amorij et al., 2007). This can be attributed 
to rapid degradation of the antigen in the GIT and/or their poor uptake by appropriate 
immune cells (Devriendt et al., 2012). This has been confirmed within our studies (Fig 5); the 
oral biodistribution of H3N2 antigen alone, shows short residence time within the GIT and 
low uptake in the target site. In contrast, bilosome formulated antigen promoted increased 
within the Peyer’s patches (Fig 5 & 6) and promote effective immune responses (Fig 7).  
23 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Orally administered bilosome vaccine containing the influenza vaccine compared to 
the Empty bilosome vesicles for (A) Median temperature differential (°C) and (B) total 
inflammatory cell count from nasal washes. 
 
Conclusions 
Whilst it is clear that oral vaccination offers a wider range of advantages, for this route to be 
more effectively exploited and commercialised, the key question to be addressed is how 
much antigen needs to be given to generate an effective immune response – when given 
orally, considerably higher doses of unformulated antigen is required compared to the 
intramuscular route. Therefore the ability of the above outlined bilosome formulation to 
enhance delivery of antigens directly addresses this critical point in the development of oral 
vaccines.  Using Design of experiments an optimised bilosome formulation has been 
identified, which contained 5:4:1 MPG:Chol:DCP respectively with 70-120 mM Bile salt. In 
A 
B 
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terms of physico-chemical characteristics, DCP content is the parameter controlling both the 
zeta potential and pH suspension, as might be expected, but the addition of DCP does not 
alter the vesicle size; bile salt content is the controlling factor for vesicle size. The optimised 
bilosome formulation showed excellent antigen retention in simulated gastric conditions, with 
no notable loss of antigen, however when exposed to simulated intestinal conditions, 28 % of 
the originally incorporated antigen was lost. Using the bilosome carrier, antigen delivery to 
the MSN was significantly improved compared to free antigen, and vaccination of ferrets 
with rHA incorporated into bilosomes was able to reduce fever and suppress lung 
inflammation in a challenge model. Thus, the bilosome platform has shown promising results 
in obtaining higher immune responses obtained in-vivo and preventing fever in the ferret 
model. Further studies to optimise the bilosomes in terms of providing an antigen dose which 
is commercially viable are being carried out.  
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